Cancer Vaccines
- Name
- Cancer Vaccines
- Accession Number
- DBCAT001835
- Description
Not Available
- Drugs
Drug Drug Description Sipuleucel-T An autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. VEGFR2-169 VEGFR2-169 is under investigation in clinical trial NCT00655785 (Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer (Phase1/2)). Nelipepimut-S Investigated for use/treatment in prostate cancer and breast cancer. - Drugs & Drug Targets